Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 887,867 | 845,042 | 679,089 | 744,844 | 582,131 |
| Depreciation Amortization | 129,936 | 114,908 | 111,900 | 104,596 | 95,998 |
| Income taxes - deferred | -24,194 | -48,306 | -35,065 | -3,377 | -38,082 |
| Accounts receivable | -28,280 | -53,871 | -41,398 | -33,141 | -60,722 |
| Accounts payable and accrued liabilities | 8,086 | -557 | 3,467 | 11,233 | 981 |
| Other Working Capital | -133,238 | -72,429 | -273,530 | -137,523 | -31,761 |
| Other Operating Activity | 88,824 | 121,723 | 98,521 | 68,914 | 99,518 |
| Operating Cash Flow | $929,001 | $906,510 | $542,984 | $755,546 | $648,063 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 554 | 8,377 | -25,000 | N/A | -250 |
| PPE Investments | -120,922 | -133,631 | -148,838 | -119,549 | -106,958 |
| Net Acquisitions | -76,694 | N/A | -11,512 | -173,418 | -1,500 |
| Purchase Sale Intangibles | -10,000 | N/A | -10,000 | N/A | -668 |
| Other Investing Activity | -10,000 | 0 | -10,000 | 0 | -668 |
| Investing Cash Flow | $-207,062 | $-125,254 | $-195,350 | $-292,967 | $-109,376 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 73,500 | -289,625 |
| Debt Issued | N/A | N/A | N/A | N/A | 200,000 |
| Debt Repayment | -75,000 | -75,000 | -75,000 | -50,000 | N/A |
| Common Stock Issued | 44,492 | 47,034 | 35,747 | 46,565 | 51,328 |
| Common Stock Repurchased | -847,565 | -81,895 | -830,317 | -762,339 | -203,418 |
| Other Financing Activity | 0 | -332,135 | 498,634 | -5,140 | -6,701 |
| Financing Cash Flow | $-878,073 | $-441,996 | $-370,936 | $-697,414 | $-248,416 |
| Exchange Rate Effect | -9,532 | 2,126 | -8,606 | -4,639 | 3,331 |
| Beginning Cash Position | 453,932 | 112,546 | 144,454 | 383,928 | 90,326 |
| End Cash Position | 288,266 | 453,932 | 112,546 | 144,454 | 383,928 |
| Net Cash Flow | $-165,666 | $341,386 | $-31,908 | $-239,474 | $293,602 |
| Free Cash Flow | |||||
| Operating Cash Flow | 929,001 | 906,510 | 542,984 | 755,546 | 648,063 |
| Capital Expenditure | -120,922 | -133,631 | -148,838 | -119,549 | -106,958 |
| Free Cash Flow | 808,079 | 772,879 | 394,146 | 635,997 | 541,105 |